Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

SRXH vs TDOC vs AMWL vs OPRX vs DOCS

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
SRXH
SRx Health Solutions Inc.

Drug Manufacturers - General

HealthcareNYSE • US
Market Cap$1M
5Y Perf.-94.2%
TDOC
Teladoc Health, Inc.

Medical - Healthcare Information Services

HealthcareNYSE • US
Market Cap$1.26B
5Y Perf.-3.2%
AMWL
American Well Corporation

Medical - Healthcare Information Services

HealthcareNYSE • US
Market Cap$129M
5Y Perf.+5.7%
OPRX
OptimizeRx Corporation

Medical - Healthcare Information Services

HealthcareNASDAQ • US
Market Cap$124M
5Y Perf.-27.3%
DOCS
Doximity, Inc.

Medical - Healthcare Information Services

HealthcareNYSE • US
Market Cap$5.24B
5Y Perf.-54.2%

SRXH vs TDOC vs AMWL vs OPRX vs DOCS — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
SRXH logoSRXH
TDOC logoTDOC
AMWL logoAMWL
OPRX logoOPRX
DOCS logoDOCS
IndustryDrug Manufacturers - GeneralMedical - Healthcare Information ServicesMedical - Healthcare Information ServicesMedical - Healthcare Information ServicesMedical - Healthcare Information Services
Market Cap$1M$1.26B$129M$124M$5.24B
Revenue (TTM)$119M$2.51B$182M$109M$638M
Net Income (TTM)$-11M$-171M$-88M$5M$239M
Gross Margin19.9%65.6%38.7%67.3%89.7%
Operating Margin-4.9%-7.6%-50.6%10.7%37.4%
Forward P/E7.0x16.8x
Total Debt$39M$1.04B$5M$5M$12M
Cash & Equiv.$2M$781M$182M$23M$210M

SRXH vs TDOC vs AMWL vs OPRX vs DOCSLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

SRXH
TDOC
AMWL
OPRX
DOCS
StockApr 25May 26Return
SRx Health Solution… (SRXH)1005.8-94.2%
Teladoc Health, Inc. (TDOC)10096.8-3.2%
American Well Corpo… (AMWL)100105.7+5.7%
OptimizeRx Corporat… (OPRX)10072.7-27.3%
Doximity, Inc. (DOCS)10045.8-54.2%

Price return only. Dividends and distributions are not included.

Quick Verdict: SRXH vs TDOC vs AMWL vs OPRX vs DOCS

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: DOCS leads in 3 of 7 categories (5-stock set), making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. SRx Health Solutions Inc. is the stronger pick specifically for growth and revenue expansion. AMWL and OPRX also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
SRXH
SRx Health Solutions Inc.
The Growth Leader

SRXH is the #2 pick in this set and the best alternative if growth is your priority.

  • 28.4% revenue growth vs AMWL's -2.0%
Best for: growth
TDOC
Teladoc Health, Inc.
The Healthcare Pick

Among these 5 stocks, TDOC doesn't own a clear edge in any measured category.

Best for: healthcare exposure
AMWL
American Well Corporation
The Momentum Pick

AMWL ranks third and is worth considering specifically for momentum.

  • +14.3% vs SRXH's -84.6%
Best for: momentum
OPRX
OptimizeRx Corporation
The Growth Play

OPRX is the clearest fit if your priority is growth exposure and long-term compounding.

  • Rev growth 18.8%, EPS growth 124.5%, 3Y rev CAGR 20.6%
  • 110.5% 10Y total return vs DOCS's -50.9%
  • Lower P/E (7.0x vs 16.8x)
Best for: growth exposure and long-term compounding
DOCS
Doximity, Inc.
The Income Pick

DOCS carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.

  • beta 1.03
  • Lower volatility, beta 1.03, Low D/E 1.1%, current ratio 6.97x
  • Beta 1.03, current ratio 6.97x
  • 37.5% margin vs AMWL's -48.2%
Best for: income & stability and sleep-well-at-night
See the full category breakdown
CategoryWinnerWhy
GrowthSRXH logoSRXH28.4% revenue growth vs AMWL's -2.0%
ValueOPRX logoOPRXLower P/E (7.0x vs 16.8x)
Quality / MarginsDOCS logoDOCS37.5% margin vs AMWL's -48.2%
Stability / SafetyDOCS logoDOCSBeta 1.03 vs OPRX's 2.28, lower leverage
DividendsTieNone of these 5 stocks pay a meaningful dividend
Momentum (1Y)AMWL logoAMWL+14.3% vs SRXH's -84.6%
Efficiency (ROA)DOCS logoDOCS20.7% ROA vs AMWL's -25.1%, ROIC 20.0% vs -95.1%

SRXH vs TDOC vs AMWL vs OPRX vs DOCS — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

SRXHSRx Health Solutions Inc.

Segment breakdown not available.

TDOCTeladoc Health, Inc.
FY 2025
Other
100.0%$438M
AMWLAmerican Well Corporation
FY 2025
Platform Subscription
53.1%$132M
Visits
37.8%$94M
Others
9.1%$23M
OPRXOptimizeRx Corporation

Segment breakdown not available.

DOCSDoximity, Inc.
FY 2025
Subscription
95.3%$544M
Service, Other
4.7%$27M

SRXH vs TDOC vs AMWL vs OPRX vs DOCS — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLDOCSLAGGINGOPRX

Income & Cash Flow (Last 12 Months)

DOCS leads this category, winning 5 of 6 comparable metrics.

TDOC is the larger business by revenue, generating $2.5B annually — 23.0x OPRX's $109M. DOCS is the more profitable business, keeping 37.5% of every revenue dollar as net income compared to AMWL's -48.2%. On growth, DOCS holds the edge at +9.8% YoY revenue growth, suggesting stronger near-term business momentum.

MetricSRXH logoSRXHSRx Health Soluti…TDOC logoTDOCTeladoc Health, I…AMWL logoAMWLAmerican Well Cor…OPRX logoOPRXOptimizeRx Corpor…DOCS logoDOCSDoximity, Inc.
RevenueTrailing 12 months$119M$2.5B$182M$109M$638M
EBITDAEarnings before interest/tax$42M-$59M$16M$250M
Net IncomeAfter-tax profit-$171M-$88M$5M$239M
Free Cash FlowCash after capex$251M-$42M$12M$314M
Gross MarginGross profit ÷ Revenue+19.9%+65.6%+38.7%+67.3%+89.7%
Operating MarginEBIT ÷ Revenue-4.9%-7.6%-50.6%+10.7%+37.4%
Net MarginNet income ÷ Revenue-9.4%-6.8%-48.2%+4.7%+37.5%
FCF MarginFCF ÷ Revenue+1.3%+10.0%-22.9%+10.6%+49.2%
Rev. Growth (YoY)Latest quarter vs prior year-2.5%-100.0%-0.2%+9.8%
EPS Growth (YoY)Latest quarter vs prior year+32.1%+44.5%-16.2%
DOCS leads this category, winning 5 of 6 comparable metrics.

Valuation Metrics

Evenly matched — SRXH and OPRX each lead in 2 of 6 comparable metrics.

At 23.5x trailing earnings, DOCS trades at a 5% valuation discount to OPRX's 24.6x P/E. On an enterprise value basis, OPRX's 6.5x EV/EBITDA is more attractive than DOCS's 21.1x.

MetricSRXH logoSRXHSRx Health Soluti…TDOC logoTDOCTeladoc Health, I…AMWL logoAMWLAmerican Well Cor…OPRX logoOPRXOptimizeRx Corpor…DOCS logoDOCSDoximity, Inc.
Market CapShares × price$1M$1.3B$129M$124M$5.2B
Enterprise ValueMkt cap + debt − cash$29M$1.5B-$48M$105M$5.0B
Trailing P/EPrice ÷ TTM EPS-0.17x-6.11x-1.30x24.56x23.45x
Forward P/EPrice ÷ next-FY EPS est.7.04x16.83x
PEG RatioP/E ÷ EPS growth rate0.30x
EV / EBITDAEnterprise value multiple15.13x6.55x21.14x
Price / SalesMarket cap ÷ Revenue0.02x0.50x0.52x1.13x9.18x
Price / BookPrice ÷ Book value/share0.89x0.50x0.98x4.84x
Price / FCFMarket cap ÷ FCF1.20x4.40x6.62x19.64x
Evenly matched — SRXH and OPRX each lead in 2 of 6 comparable metrics.

Profitability & Efficiency

DOCS leads this category, winning 7 of 9 comparable metrics.

DOCS delivers a 24.4% return on equity — every $100 of shareholder capital generates $24 in annual profit, vs $-33 for AMWL. DOCS carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to TDOC's 0.75x. On the Piotroski fundamental quality scale (0–9), DOCS scores 9/9 vs SRXH's 3/9, reflecting strong financial health.

MetricSRXH logoSRXHSRx Health Soluti…TDOC logoTDOCTeladoc Health, I…AMWL logoAMWLAmerican Well Cor…OPRX logoOPRXOptimizeRx Corpor…DOCS logoDOCSDoximity, Inc.
ROE (TTM)Return on equity-12.4%-33.5%+4.2%+24.4%
ROA (TTM)Return on assets-22.4%-5.9%-25.1%+3.0%+20.7%
ROICReturn on invested capital-18.1%-11.5%-95.1%+7.1%+20.0%
ROCEReturn on capital employed-98.8%-10.0%-36.6%+7.6%+22.3%
Piotroski ScoreFundamental quality 0–936689
Debt / EquityFinancial leverage0.75x0.02x0.04x0.01x
Net DebtTotal debt minus cash$37M$259M-$178M-$19M-$197M
Cash & Equiv.Liquid assets$2M$781M$182M$23M$210M
Total DebtShort + long-term debt$39M$1.0B$5M$5M$12M
Interest CoverageEBIT ÷ Interest expense-2.83x-8.76x-239.18x1.26x
DOCS leads this category, winning 7 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

DOCS leads this category, winning 3 of 6 comparable metrics.

A $10,000 investment in DOCS five years ago would be worth $4,911 today (with dividends reinvested), compared to $278 for AMWL. Over the past 12 months, AMWL leads with a +14.3% total return vs SRXH's -84.6%. The 3-year compound annual growth rate (CAGR) favors DOCS at -8.8% vs SRXH's -62.3% — a key indicator of consistent wealth creation.

MetricSRXH logoSRXHSRx Health Soluti…TDOC logoTDOCTeladoc Health, I…AMWL logoAMWLAmerican Well Cor…OPRX logoOPRXOptimizeRx Corpor…DOCS logoDOCSDoximity, Inc.
YTD ReturnYear-to-date-52.9%-1.3%+59.8%-46.6%-39.9%
1-Year ReturnPast 12 months-84.6%+1.5%+14.3%-30.1%-55.4%
3-Year ReturnCumulative with dividends-94.6%-73.3%-80.7%-54.4%-24.2%
5-Year ReturnCumulative with dividends-94.6%-95.4%-97.2%-87.3%-50.9%
10-Year ReturnCumulative with dividends-94.6%-41.1%-98.3%+110.5%-50.9%
CAGR (3Y)Annualised 3-year return-62.3%-35.6%-42.2%-23.0%-8.8%
DOCS leads this category, winning 3 of 6 comparable metrics.

Risk & Volatility

Evenly matched — SRXH and AMWL each lead in 1 of 2 comparable metrics.

SRXH is the less volatile stock with a -0.32 beta — it tends to amplify market swings less than OPRX's 2.28 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AMWL currently trades 84.7% from its 52-week high vs SRXH's 9.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricSRXH logoSRXHSRx Health Soluti…TDOC logoTDOCTeladoc Health, I…AMWL logoAMWLAmerican Well Cor…OPRX logoOPRXOptimizeRx Corpor…DOCS logoDOCSDoximity, Inc.
Beta (5Y)Sensitivity to S&P 500-0.32x1.91x1.47x2.28x1.03x
52-Week HighHighest price in past year$1.25$9.77$9.15$22.25$76.51
52-Week LowLowest price in past year$0.08$4.40$3.71$5.54$20.55
% of 52W HighCurrent price vs 52-week peak+9.0%+71.2%+84.7%+29.8%+34.0%
RSI (14)Momentum oscillator 0–10041.474.167.146.960.1
Avg Volume (50D)Average daily shares traded22.0M5.5M59K476K2.7M
Evenly matched — SRXH and AMWL each lead in 1 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: TDOC as "Hold", OPRX as "Buy", DOCS as "Buy". Consensus price targets imply 156.4% upside for OPRX (target: $17) vs 8.9% for TDOC (target: $8).

MetricSRXH logoSRXHSRx Health Soluti…TDOC logoTDOCTeladoc Health, I…AMWL logoAMWLAmerican Well Cor…OPRX logoOPRXOptimizeRx Corpor…DOCS logoDOCSDoximity, Inc.
Analyst RatingConsensus buy/hold/sellHoldBuyBuy
Price TargetConsensus 12-month target$7.58$17.00$42.79
# AnalystsCovering analysts421522
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises1
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%+0.0%0.0%+2.3%
Insufficient data to determine a leader in this category.
Key Takeaway

DOCS leads in 3 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 2 categories are tied.

Best OverallDoximity, Inc. (DOCS)Leads 3 of 6 categories
Loading custom metrics...

SRXH vs TDOC vs AMWL vs OPRX vs DOCS: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is SRXH or TDOC or AMWL or OPRX or DOCS a better buy right now?

For growth investors, SRx Health Solutions Inc.

(SRXH) is the stronger pick with 28. 4% revenue growth year-over-year, versus -2. 0% for American Well Corporation (AMWL). Doximity, Inc. (DOCS) offers the better valuation at 23. 5x trailing P/E (16. 8x forward), making it the more compelling value choice. Analysts rate OptimizeRx Corporation (OPRX) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — SRXH or TDOC or AMWL or OPRX or DOCS?

On trailing P/E, Doximity, Inc.

(DOCS) is the cheapest at 23. 5x versus OptimizeRx Corporation at 24. 6x. On forward P/E, OptimizeRx Corporation is actually cheaper at 7. 0x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — SRXH or TDOC or AMWL or OPRX or DOCS?

Over the past 5 years, Doximity, Inc.

(DOCS) delivered a total return of -50. 9%, compared to -97. 2% for American Well Corporation (AMWL). Over 10 years, the gap is even starker: OPRX returned +110. 5% versus AMWL's -98. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — SRXH or TDOC or AMWL or OPRX or DOCS?

By beta (market sensitivity over 5 years), SRx Health Solutions Inc.

(SRXH) is the lower-risk stock at -0. 32β versus OptimizeRx Corporation's 2. 28β — meaning OPRX is approximately -805% more volatile than SRXH relative to the S&P 500. On balance sheet safety, Doximity, Inc. (DOCS) carries a lower debt/equity ratio of 1% versus 75% for Teladoc Health, Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — SRXH or TDOC or AMWL or OPRX or DOCS?

By revenue growth (latest reported year), SRx Health Solutions Inc.

(SRXH) is pulling ahead at 28. 4% versus -2. 0% for American Well Corporation (AMWL). On earnings-per-share growth, the picture is similar: OptimizeRx Corporation grew EPS 124. 5% year-over-year, compared to 54. 2% for Doximity, Inc.. Over a 3-year CAGR, OPRX leads at 20. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — SRXH or TDOC or AMWL or OPRX or DOCS?

Doximity, Inc.

(DOCS) is the more profitable company, earning 39. 1% net margin versus -38. 4% for American Well Corporation — meaning it keeps 39. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DOCS leads at 39. 9% versus -42. 2% for AMWL. At the gross margin level — before operating expenses — DOCS leads at 90. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is SRXH or TDOC or AMWL or OPRX or DOCS more undervalued right now?

On forward earnings alone, OptimizeRx Corporation (OPRX) trades at 7.

0x forward P/E versus 16. 8x for Doximity, Inc. — 9. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for OPRX: 156. 4% to $17. 00.

08

Which pays a better dividend — SRXH or TDOC or AMWL or OPRX or DOCS?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

09

Is SRXH or TDOC or AMWL or OPRX or DOCS better for a retirement portfolio?

For long-horizon retirement investors, SRx Health Solutions Inc.

(SRXH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 32)). Teladoc Health, Inc. (TDOC) carries a higher beta of 1. 91 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SRXH: -94. 6%, TDOC: -41. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between SRXH and TDOC and AMWL and OPRX and DOCS?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: SRXH is a small-cap high-growth stock; TDOC is a small-cap quality compounder stock; AMWL is a small-cap quality compounder stock; OPRX is a small-cap high-growth stock; DOCS is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

SRXH

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 14%
Run This Screen
Stocks Like

TDOC

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 39%
Run This Screen
Stocks Like

AMWL

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 23%
Run This Screen
Stocks Like

OPRX

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 40%
Run This Screen
Stocks Like

DOCS

Quality Mega-Cap Compounder

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 22%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform SRXH and TDOC and AMWL and OPRX and DOCS on the metrics below

Revenue Growth>
%
(SRXH: 28.4% · TDOC: -2.5%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.